Compass Pathways (NASDAQ:CMPS) Shares Up 5.9% – What’s Next?

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS)’s share price traded up 5.9% during mid-day trading on Monday . The company traded as high as $14.00 and last traded at $14.1150. Approximately 1,467,043 shares changed hands during mid-day trading, a decline of 60% from the average daily volume of 3,650,261 shares. The stock had previously closed at $13.33.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on CMPS. Wall Street Zen lowered shares of Compass Pathways from a “sell” rating to a “strong sell” rating in a research note on Monday. Raymond James Financial reiterated a “buy” rating on shares of Compass Pathways in a research note on Friday, May 22nd. Wolfe Research reiterated an “outperform” rating on shares of Compass Pathways in a report on Tuesday, July 7th. Oppenheimer reissued an “outperform” rating on shares of Compass Pathways in a research report on Wednesday, August 5th. Finally, Morgan Stanley upped their price objective on Compass Pathways from $17.00 to $18.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $23.36.

Compass Pathways Trading Up 6.0%

The company has a debt-to-equity ratio of 0.60, a current ratio of 1.30 and a quick ratio of 1.30. The stock’s 50-day moving average is $12.85 and its two-hundred day moving average is $9.82. The company has a market cap of $1.96 billion, a P/E ratio of -3.07 and a beta of 2.50.

Compass Pathways (NASDAQ:CMPS) last announced its earnings results on Wednesday, August 5th. The company reported ($1.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($1.49). As a group, equities research analysts predict that Compass Pathways PLC Sponsored ADR will post -1.26 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Ancora Advisors LLC bought a new stake in Compass Pathways during the second quarter valued at about $43,000. EverSource Wealth Advisors LLC increased its stake in Compass Pathways by 67.7% during the first quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock worth $26,000 after acquiring an additional 1,920 shares during the last quarter. Persistent Asset Partners Ltd purchased a new stake in Compass Pathways during the fourth quarter valued at approximately $38,000. Caitong International Asset Management Co. Ltd purchased a new position in Compass Pathways during the 4th quarter worth $47,000. Finally, Advisory Services Network LLC purchased a new position in shares of Compass Pathways during the third quarter valued at $41,000. Institutional investors own 46.19% of the company’s stock.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.